A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Clinical trial NCT07630974 · RECRUITING
Trial details
- NCT number
- NCT07630974
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-06
- Primary completion
- 2031-08-17
- Enrollment
- 134
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.